Objectives and achievements of medicines regulation in the UK

  • M. D. Rawlins
Part of the CMR Workshop Series book series (CMRWS)


  1. 1.

    Medicines regulation in the United Kingdom is concerned with protecting both the public health and the public purse.

  2. 2.

    In protecting the public health, the safety of marketed medicinal products during normal conditions of use is the predominant objective of drug regulation.

  3. 3.

    The Licensing Authority and the Committee on Safety of Medicines rely on three strategies — the control of quality, rigorous pre-marketing safety studies and post-marketing surveillance.

  4. 4.

    Since the early 1970s, through enactment of the Medicines Act and an emerging philosophy of rational prescribing by the medical profession, reasonable evidence of efficacy, as well as safety of a drug, has been required.

  5. 5.

    To protect the public purse, successive UK governments have tried to balance the dual objectives of cost-effective prescribing within the National Health Service and the promotion of a successful pharmaceutical industry, able to contribute to employment, exports and the economy as a whole.



Adverse Drug Reaction National Health Service Drug Regulation Reasonable Evidence License Authority 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jayasuriya D C (1985). Regulation of Pharmaceuticals in Developing Countries. (Geneva: World Health Organization),Google Scholar
  2. 2.
    Dunlop D (1967). The Assessment of the Safety of Drugs and the role of Government in their Control. J. Clin. Pharmacol. 1, 184–92Google Scholar
  3. 2.
    Medicines Act (1968). (London: Her Majesty’s Stationery Office)Google Scholar
  4. 4.
    Commission of the European Communities (1984). The Rufes Governing Medicaments in the European Community. (Luxembourg: Office for Official Publications of the European Communities)Google Scholar
  5. 5.
    Zbinden G (1981). Scope and Limitation of Animal Models for the Prediction of Human Toxicity. In Brown SS and Davies DS (eds). Organ-Directed Toxicity, pp. 3–7. (Oxford: Pergamon Press)Google Scholar
  6. 6.
    Fletcher A P (1978). Drug Safety Testing and Subsequent Clinical Experience. J. R. Soc. Med. 71, 693–6PubMedGoogle Scholar
  7. 7.
    Griffin J P (1983). Repeat-dose long-term toxicity studies. In Balls M, Riddell R J and Worden A N (eds). Animals and Alternatives in Toxicity Testing, pp. 98–103. (London: Academic Press)Google Scholar
  8. 8.
    Laurence D R, Maclean A and Weatherall M (1984). Safety Testing of New Drugs. (London: Academic Press)Google Scholar
  9. 9.
    Rawlins M D and Thompson J W (1985). Mechanisms of adverse drug reactions. In Davies D M (ed). Textbook of Adverse Drug Reactions pp. 12–38, (Oxford: Oxford University Press)Google Scholar
  10. 10.
    Royal Society Study Group (1983). Risk Assessment. (London: The Royal Society)Google Scholar
  11. 11.
    Rawlins M D (1987). Advantages and disadvantages of different techniques of post-marketing surveillance. In Mann R D (ed). Adverse Drug Reactions pp. 67–74. (Carnforth: Parthenon Publishing)Google Scholar
  12. 12.
    Rawlins M D (1988). Spontaneous reporting of adverse drug reactions I: the data. Br. J. Clin. Pharmacol. 26, 1–6PubMedGoogle Scholar
  13. 13.
    Rawlins M D (1988). Spontaneous reporting of adverse drug reactions II: uses. Br. J. Clin. Pharmacol. 26, 7–12PubMedGoogle Scholar
  14. 14.
    Grahame-Smith D G (1987). Adverse drug reaction monitoring: the way forward. In Mann R D (ed). Adverse Drug Reactions pp. 201–14. (Carnforth: Parthenon Publishing)Google Scholar
  15. 15.
    Dukes G (1985). The Effect of Drug Regulation. (Lancaster: MTP Press)Google Scholar
  16. 16.
    Medewar C (1987). Observations on the UK Government’s 1987 Study of Control of Medicines. (London: Social Audit)Google Scholar
  17. 17.
    Green D G (1987). Medicines in the Marketplace. (London: IEA Health Unit)Google Scholar
  18. 18.
    Rawlins M D (1988). Drug regulation: evolution or revolution? Br. Med. J., 296, 379–80CrossRefGoogle Scholar
  19. 19.
    Rawlins M D (1984). Doctors and the drug makers, Lancet, 2, 276–8PubMedCrossRefGoogle Scholar
  20. 20.
    Office of Health Economics (1986). Crisis in Research. (London: Office of Health Economics)Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • M. D. Rawlins

There are no affiliations available

Personalised recommendations